6 Einträge gefunden

1. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆

   1. Denkert, C
   2. Untch, M
   3. Benz, S
   4. Schneeweiss, A
   5. Weber, K E
   6. Schmatloch, S
   7. Jackisch, C

   2021 - Forschungsinformationssystem des UKE
2. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial

   1. Möbus, V
   2. Jackisch, C
   3. Lück, H J
   4. du Bois, A
   5. Thomssen, C
   6. Kuhn, W
   7. Nitz, U

   2018 - Forschungsinformationssystem des UKE
3. German Adjuvant Intergroup Node-positive Study (GAIN):a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients

   1. Möbus, V
   2. von Minckwitz, G
   3. Jackisch, C
   4. Lück, H-J
   5. Schneeweiss, A
   6. Tesch, H
   7. Elling, D

   2017 - Forschungsinformationssystem des UKE
4. Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers

   1. Jackisch, C
   2. Müller, V
   3. Dall, P
   4. Neumeister, R
   5. Park-Simon, T-W
   6. Ruf-Dördelmann, A
   7. Seiler, S

   2015 - Forschungsinformationssystem des UKE
5. Subcutaneous Administration of Monoclonal Antibodies in Oncology

   1. Jackisch, C
   2. Müller, V
   3. Maintz, C
   4. Hell, S
   5. Ataseven, B

   2014 - Forschungsinformationssystem des UKE
6. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.

   1. Eiermann, W
   2. Rezai, M
   3. Kümmel, S
   4. Kühn, T
   5. Warm, M
   6. Friedrichs, K
   7. Schneeweiss, A

   2013 - Forschungsinformationssystem des UKE